Suppression of tumor immune microenvironment via microRNA‐1 after epidermal growth factor receptor‐tyrosine kinase inhibitor resistance acquirement in lung adenocarcinoma
暂无分享,去创建一个
[1] S. Tomida,et al. Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation–Positive Non–Small Cell Lung Cancer , 2020, Clinical Cancer Research.
[2] Ke Li,et al. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression , 2019, Molecular Cancer.
[3] T. Yamanaka,et al. The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.
[4] V. De Rosa,et al. The Multifaceted Interface Between Cytokines and microRNAs: An Ancient Mechanism to Regulate the Good and the Bad of Inflammation , 2018, Front. Immunol..
[5] S Senan,et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] A. Jemal,et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.
[7] Stephen Broderick,et al. Neoadjuvant PD‐1 Blockade in Resectable Lung Cancer , 2018, The New England journal of medicine.
[8] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[9] T. Mitsudomi,et al. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[10] V. Gebski,et al. Checkpoint Inhibitors in Metastatic EGFR‐Mutated Non–Small Cell Lung Cancer—A Meta‐Analysis , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[11] S. Yuspa,et al. Cell autonomous or systemic EGFR blockade alters the immune‐environment in squamous cell carcinomas , 2016, International journal of cancer.
[12] C. Weaver,et al. IL-6 promotes the differentiation of a subset of naive CD8+ T cells into IL-21–producing B helper CD8+ T cells , 2016, The Journal of experimental medicine.
[13] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[14] S. Eliason,et al. MicroRNA-200c Represses IL-6, IL-8, and CCL-5 Expression and Enhances Osteogenic Differentiation , 2016, PloS one.
[15] K. O'Byrne,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. , 2016, The Lancet. Oncology.
[16] J. Shan,et al. Rotenone Susceptibility Phenotype in Olfactory Derived Patient Cells as a Model of Idiopathic Parkinson’s Disease , 2016, PloS one.
[17] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[18] A. Jemal,et al. Long-Term Realism and Cost-Effectiveness: Primary Prevention in Combatting Cancer and Associated Inequalities Worldwide , 2015, Journal of the National Cancer Institute.
[19] Thomas J. Smith,et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] Jia-Nan Cheng,et al. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB. , 2015, Biochemical and biophysical research communications.
[21] Bin Zhang,et al. Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma , 2015, Oncotarget.
[22] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[23] K. Ansel,et al. MicroRNA regulation of lymphocyte tolerance and autoimmunity. , 2015, The Journal of clinical investigation.
[24] H. Ditzel,et al. Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[25] L. Sequist,et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. , 2015, The Lancet. Oncology.
[26] Shingo Matsumoto,et al. Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer. , 2015, Translational lung cancer research.
[27] H. Sasano,et al. An activation of LC3A‐mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma , 2014, The Journal of pathology.
[28] I. Ismail,et al. Nanoscale Diblock Copolymer Micelles: Characterizations and Estimation of the Effective Diffusion Coefficients of Biomolecules Release through Cylindrical Diffusion Model , 2014, PloS one.
[29] C. Creighton,et al. miR-1 and miR-133b Are Differentially Expressed in Patients with Recurrent Prostate Cancer , 2014, PloS one.
[30] W. Pao,et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. , 2014, Cancer discovery.
[31] S. Greenberg,et al. Inhibition of Myogenic MicroRNAs 1, 133, and 206 by Inflammatory Cytokines Links Inflammation and Muscle Degeneration in Adult Inflammatory Myopathies , 2014, Arthritis & rheumatology.
[32] Koichi Goto,et al. RET fusion gene: Translation to personalized lung cancer therapy , 2013, Cancer science.
[33] Chun-Ming Tsai,et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] Xiaonan H. Wang. MicroRNA in myogenesis and muscle atrophy , 2013, Current opinion in clinical nutrition and metabolic care.
[35] P. Jänne,et al. New targetable oncogenes in non-small-cell lung cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] Pengyuan Yang,et al. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1. , 2012, Life sciences.
[37] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[38] D. Cooper,et al. Differential Regulation of the Let-7 Family of MicroRNAs in CD4+ T Cells Alters IL-10 Expression , 2012, The Journal of Immunology.
[39] Alison P. Klein,et al. Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.
[40] W. Pao,et al. Chipping away at the lung cancer genome , 2012, Nature Medicine.
[41] E. Felip,et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.
[42] Jun Ma,et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. , 2011, The Lancet. Oncology.
[43] A. Gemma,et al. F1000 highlights , 2010 .
[44] S. Toyooka,et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. , 2010, The Lancet. Oncology.
[45] F. Hirsch,et al. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[46] Y. Hayashizaki,et al. Cancer research with non‐coding RNA , 2006, Cancer science.
[47] C. Croce,et al. MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.
[48] H. Horvitz,et al. MicroRNA expression profiles classify human cancers , 2005, Nature.
[49] M. Meyerson,et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.
[50] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[51] David E. Misek,et al. RANTES expression is a predictor of survival in stage I lung adenocarcinoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[52] T. Tuschl,et al. Identification of Novel Genes Coding for Small Expressed RNAs , 2001, Science.
[53] D. Taub,et al. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. , 1996, The Journal of clinical investigation.
[54] J. Roa,et al. miR-1 and miR-145 act as tumor suppressor microRNAs in gallbladder cancer. , 2014, International journal of clinical and experimental pathology.